| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Topoisomerase I
The primary biological target of T-2513 is topoisomerase I, an enzyme that relieves torsional stress in DNA during replication and transcription. T-2513 binds covalently to the topoisomerase I-DNA complex and stabilizes it, preventing the religation of the DNA strand. This leads to the accumulation of DNA breaks, which block DNA replication and RNA synthesis, ultimately causing cell death. This mechanism of action is shared with other camptothecin derivatives, such as irinotecan and topotecan. |
|---|---|
| ln Vitro |
The metabolite of T-2513 is SN-38[1]. T-2513 exhibits widespread cytotoxicity towards many human tumor cell lines [2].
In vitro, T-2513 is a potent and specific inhibitor of topoisomerase I. It forms covalent bonds with the topoisomerase I-DNA complex, enhancing its stability. This interaction disrupts DNA replication and RNA synthesis, ultimately resulting in cellular apoptosis. The compound's antiproliferative activity against cancer cell lines is assessed using standard cell viability assays. The inhibition of topoisomerase I is confirmed by measuring the stabilization of the enzyme-DNA complex using a DNA relaxation assay. |
| ln Vivo |
T-2513 (1-100 mg/kg) indicates Walker-256 cancer Antitumor Activity[2].
Information regarding the in vivo activity of T-2513 in animal models is limited. Its biological activity has been characterized primarily through in vitro assays. The compound's potent in vitro activity and its mechanism of action suggest it may have in vivo efficacy, but this has not been extensively studied. Further studies are required to determine its pharmacokinetic properties, bioavailability, and efficacy in animal models of cancer. |
| Enzyme Assay |
The non-cellular enzyme or receptor binding assay for T-2513 involves measuring its inhibition of topoisomerase I activity. This is typically performed using a DNA relaxation assay with purified topoisomerase I enzyme and supercoiled DNA. The conversion of supercoiled DNA to relaxed DNA is assessed by gel electrophoresis. In the presence of the inhibitor, the rate of relaxation is reduced. The compound's ability to stabilize the enzyme-DNA complex is assessed by measuring the persistence of the cleaved complex.
|
| Cell Assay |
Cell Cytotoxicity Assay[2]
Cell Types: WiDr, HT-29, SK-BR-3, MKN-1, SK-LU-1, LX-1, KB, and HeLaS3 cells Tested Concentrations: 15.1- 111.5 ng/mL Incubation Duration: 24 hrs (hours) Experimental Results: demonstrated cytotoxicity against a panel of human tumor cell lines with GI50s of 32.1, 97.6, 38.6, 15.6, 111.5, 15.1, 34.0, and 50.9 ng/mL for WiDr, HT-29, SK-BR-3, MKN-1, SK-LU-1, LX-1, KB, and HeLaS3 cells, respectively. The in vitro cellular assay for T-2513 involves treating cancer cell lines with various concentrations of the compound. Cell viability is assessed using standard assays such as MTT or SRB to determine the IC50. The induction of DNA damage is assessed by measuring the phosphorylation of histone H2AX (γ-H2AX) using immunofluorescence or western blotting. Apoptosis is evaluated using flow cytometry with Annexin V/PI staining or by measuring caspase-3/7 activity. |
| Animal Protocol |
Animal/Disease Models: Rats bearing Walker-256 carcinoma[2]
Doses: 1, 10, and 100 mg/kg Route of Administration: Experimental Results: The ED50 was 23 mg/kg. The in vivo animal experiment workflow for T-2513 has not been well-established. If an animal study were to be designed, a xenograft model using a cancer cell line in immunodeficient mice would be appropriate. The compound would be administered at various doses and routes. Tumor growth would be monitored by measuring tumor volume. At the end of the study, tumors would be excised and analyzed for markers of topoisomerase I inhibition and apoptosis. |
| References |
|
| Molecular Formula |
C25H27N3O5
|
|---|---|
| Molecular Weight |
449.50
|
| Exact Mass |
449.195
|
| Elemental Analysis |
C, 66.80; H, 6.05; N, 9.35; O, 17.80
|
| CAS # |
288247-87-0
|
| Related CAS # |
288247-87-0
|
| PubChem CID |
9848248
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.069
|
| tPSA |
116.67
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
33
|
| Complexity |
885
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O1C([C@](C([H])([H])C([H])([H])[H])(C2C([H])=C3C4C(=C(C([H])([H])C([H])([H])[H])C5C([H])=C(C([H])=C([H])C=5N=4)OC([H])([H])C([H])([H])C([H])([H])N([H])[H])C([H])([H])N3C(C=2C1([H])[H])=O)O[H])=O
|
| InChi Key |
XZLHHOGJQUVONU-VWLOTQADSA-N
|
| InChi Code |
InChI=1S/C25H27N3O5/c1-3-15-16-10-14(32-9-5-8-26)6-7-20(16)27-22-17(15)12-28-21(22)11-19-18(23(28)29)13-33-24(30)25(19,31)4-2/h6-7,10-11,31H,3-5,8-9,12-13,26H2,1-2H3/t25-/m0/s1
|
| Chemical Name |
(19S)-7-(3-aminopropoxy)-10,19-diethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
|
| Synonyms |
UNII-20Y8Q506KT; T2513; T-2513; T 2513; 20Y8Q506KT
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2247 mL | 11.1235 mL | 22.2469 mL | |
| 5 mM | 0.4449 mL | 2.2247 mL | 4.4494 mL | |
| 10 mM | 0.2225 mL | 1.1123 mL | 2.2247 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|